+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure



Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure



Zhonghua Yi Xue Za Zhi 86(24): 1693-1696



To investigate the expression of the matrix metalloproteinases (MMP)-2, -3, and 9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), fibronectin (FN), and tenascin-C (TN-C) in the myocardium, and their relationship with the myocardial remodeling and heart function in the patients with congestive heart failure (CHF). A few tissues of papillary muscles of left ventricle were taken from 39 patients with mitral insufficiency during mitral valve replacement, and from 8 organ donors who had died of accidents to undergo pathological examination and to detect the protein expression of MMP-2, -3, and 9, and TIMP-1 by immunoprecipitation and the expression of FN and TN-C by immunofluorescence test. Peripheral blood samples were collected from these 39 patients and 30 normal controls to examine the plasma MMPs and TIMP-1 by ELISA. Typical myocardial remodeling was seen in the myocardial tissues of the CHF patients. The plasma levels of MMP-2, -3, and -9 of the CHF patients in the cardiac function classes II - IV were all significantly higher than those of the normal controls (P < 0.05 or P < 0.01) with a tendency to increase with the deterioration of heart function, The plasma level of TIMP-1 of the CHF patients in the cardiac function classes II - IV were all significantly higher than that of the normal controls (P < 0.05 or P < 0.01) with a tendency to decrease with the deterioration of heart function. The protein expression levels of MMP-2, -3, and -9 in the myocardium of the CHF patients in the cardiac function classes III - IV were all significantly higher than those of the normal controls (P < 0.05 or P < 0.01) with a tendency to increase with the deterioration of heart function. The protein expression levels of TIMP-1 in the myocardium of the CHF patients in the cardiac function classes III - IV were all significantly lower than that of the normal controls (P < 0.05 or P < 0.01) with a tendency to decrease with the deterioration of heart function. The protein expression levels of FN in the myocardium of the CHF patients in the cardiac function classes II - IV were all significantly lower than that of the normal controls (all P < 0.05) with a tendency to decrease with the deterioration of heart function. The protein expression levels of TN-C in the myocardium of the CHF patients in the cardiac function classes II - IV were all significantly higher than that of the normal controls (all P < 0.01) with a tendency to increase with the deterioration of heart function. The increasing expression of MMP-2, -3, and -9 and the decreasing expression of TIMP-1 contribute to the myocardial remodeling, thus changing the extracellular matrix in the myocardium tissue and leading to the development and progression of CHF.

(PDF emailed within 1 workday: $29.90)

Accession: 049407503

Download citation: RISBibTeXText

PMID: 16854324


Related references

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Expression and significance of matrix metalloproteinase-1,9, tissue inhibitor of metalloproteinase-4 and extracellular matrix metalloproteinase inducer in the myocardium of congestive heart failure in patients with rheumatic heart diseases. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 34(8): 790-795, 2011

Alteration of extracellular matrix protein profile in congestive heart failure secondary to myocardial infarction. FASEB Journal 7(3-4): A123, 1993

Myocardial extracellular matrix remodeling with the development of pacing induced congestive heart failure contributory mechanisms. Cardiovascular Pathology 7(3): 161-168, 1998

Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 116(2): 133-141, 2010

HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway. Skeletal Muscle 7(1): 20, 2018

Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transplantation Proceedings 39(7): 2344-2346, 2007

Differential regulation of extracellular matrix constituents in myocardial remodeling with and without heart failure following pressure overload. Matrix Biology 32(2): 133-142, 2013

Differential release of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients following alcohol induced myocardial infarction. Circulation 104(17 Suppl.): II 305, October 23, 2001

Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovascular Pathology 7(3): 153-159, 1998

Myocardial matrix metalloproteinase-3 and matrix metalloproteinase inhibitor-1 expression in congestive heart failure. Zhonghua Nei Ke Za Zhi 41(7): 453-455, 2002

Involvement of matrix metalloproteinases and their inhibitors in endometrial extracellular matrix turnover in Chlamydia trachomatis-infected recurrent spontaneous aborters. Pathogens and Disease 75(1), 2017

Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Acc Current Journal Review 10(3): 54-0, 2001

Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science 147: 75-100, 2017

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal 150(3): 484-487, 2005